Erythropoietin (EPO) Global Market Report 2020-30: COVID-19 Growth and Change

December 2020 •
200 pages •
Report ID: 5999219 •
Format: PDF

Summary
Table of contents

Major players in the erythropoietin (EPO) market are Amgen Inc., Johnson & Johnson, Roche Group, Pfizer Inc., Novartis, Celltrion Inc and LG Life Sciences Ltd.

The global erythropoietin (EPO) market is expected to decline from $1.01 billion in 2019 to $0.95 billion in 2020 at a compound annual growth rate (CAGR) of -6.27%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $2.27 billion in 2023 at a CAGR of 33.9%.

The erythropoietin (EPO) market consists of sales of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that manufacture erythropoietin biosimilars. Erythropoietin (EPO) is a hormone produced by kidneys and plays a vital role in the production of red blood cells, which carry oxygen from the lungs to the rest of the body. Lack of sufficient erythropoietin results in low red blood cells, which may lead to anaemia. The erythropoietin (EPO) drugs are used for treatment for anaemia, kidney disorders, cancer, and other conditions.

In August 2018, STADA Arzneimittel AG, a Germany-based pharmaceutical company, acquired majority stakes (51.34%) in Bioceuticals Arzneimittel AG for an undisclosed amount. The acquisition is expected to expand STADA Arzneimittel AG‘s presence in the biosimilar sector. Bioceuticals Arzneimittel AG licenses marketing rights to epoetin zeta and epoetin biosimilar to STADA Arzneimittel AG. Bioceuticals Arzneimittel AG is a Germany-based company engaged in manufacturing and marketing active pharmaceutical ingredients including erythropoietin biosimilars.

The erythropoietin market covered in this report is segmented by product into epoetin-alfa; epoetin-beta; darbepoetin-alfa; others and by application into cancer; hematology; renal diseases; neurology; others.

Stringent regulations imposed on the production and sales of erythropoietin drugs are predicted to hinder the growth of the erythropoietin market over the forecast period. For instance, in European Community (EC), technologically advanced medicinal products manufactured using a biotechnological process such as recombinant DNA technology should comply with marketing authorization (MA) under provisions of Regulation (EC) No. 726/04 issued by EC. The regulatory policy for biosimilars is complex and in Europe is mainly governed by guidelines issued by the European Medicines Agency (EMEA). In addition to this, recombinant human erythropoietin (rHuEPO) must fulfill additional product-class specific guidelines apart from regulations on quality, clinical, and non-clinical issues developed by the EMEA.

The rising incidence of chronic kidney diseases is anticipated to propel the demand for the erythropoietin market over the approaching years. According to the Brazilian Journal of Nephrology’s statistics published in February 2019, kidney disease is a global public healthcare problem affecting over 750 million people across the globe. In addition to this, according to the Centers for Disease Control and Prevention’s report published on chronic kidney disease in the United States, in 2019, 15% of the adults in the USA, or 37 million people are estimated to have chronic kidney disease (CKD). CKD is more common in people aged 65 or older (38%) than in people aged 45-64 years (13%) and 18-44 years (7%). Chronic kidney diseases lead to an anaemic condition which in turn increases the demand for erythropoietin to curb the condition, thereby driving the revenues for the market.

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager